The Drugs Controller General of India (DCGI) has also granted emergency use authorisation (EUA) to Cadila for its ZyCoV-D for an additional dose of 3mg with a two-jab inoculation schedule 28 days apart for those aged above 12 years.
Covaxin, one of the main vaccines administered to adults, is currently being administered to children in the age group of 15-18 years.
The findings of the study, conducted in February this year after isolating the Omicron variant, have been published in the Journal of Infection on April 5.
The WHO said in a statement late on on Saturday that the Covaxin suspension was in response to the outcomes of its post EUL (emergency use authorisation) inspection, held between March 14-22, and the need to conduct process and facility upgrades to address recently identified GMP (good manufacturing practice) deficiencies.
Bharat Biotech on April 1 announced the temporary slowing down of production of its covid-19 vaccine Covaxin across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand.
Hyderabad-based vaccine manufacturer Bharat Biotech on Friday announced the temporary slowing down of its Covid vaccine Covaxin's production across its manufacturing facilities.
With cases remaining on the higher side, both in hospitalisation and mortalities, USA will soon launch Omicron-specific vaccine in March
Covaxin is India's indigenous Covid-19 vaccine manufactured by Bharat Biotech, which has been developed in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV)
The DCGI approval came after the SEC on COVID-19 of the CDSCO on January 19 recommended granting regular market approval to the SII's Covishield and Bharat Biotech's Covaxin for use in adult population subject to certain conditions.
Dr Krishna Ella and Suchitra Ella, the couple behind Bharat Biotech, which developed India's first indigenous vaccine for Covid-19, have been awarded Padma Bhushan, the third highest civilian award in the country.
Hyderabad-based Bharat Biotech had submitted complete information on chemistry, manufacturing, and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
The cumulative COVID-19 vaccine doses administered in the country have reached 158.74 crore so far, the Union Health Ministry said on Tuesday.
Citing the study results, Bharat Biotech noted that more than 90 per cent of all individuals boosted with Covaxin showed neutralising antibodies.
COVAXIN Booster Dose Data Shows Promising Results
As per the findings, Indicative studies have shown that 3 doses of Wuhan-strain based vaccines may provide only partial protection from infection with this variant
Adding another feather in the cap of India’s vaccination drive, the much-awaited inoculation of teenagers in the 15-18 years age group kicked off across the country on Monday (January 3). About 42 lakh children in the age group were inoculated on the first day of Covid vaccination.
The vaccine used for inoculating children is Bharat Biotech's Covaxin, according to a set of new guidelines issued by the Union health ministry.
No serious adverse event was reported. 374 subjects reported either mild or moderate severity symptoms with 78.6 per cent getting resolved within one day.
According to new guidelines issued by the Union health ministry on Monday, the vaccine option against COVID-19 for children in the age group of 15-18 years, who will be inoculated from January 3, would be Covaxin only
On the ongoing RDA strike which has hit all the medical services in the national capital, the IMA said that the issue of expediting PG counselling is the need of the hour to increase manpower ahead of the looming third wave threat.
The DCGI gave its approval Friday, the source said.
The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said.
An MoU was signed to recognise Covid-19 vaccine certification by India's Ambassador to Nepal Vinay Mohan Kwatra and the Himalayan nation's Health Secretary on Tuesday.
Of eight WHO-approved vaccines against Covid-19 in emergency use listing, two vaccines -- Covaxin and Covishield -- are from India.
The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India's largest ever clinical trial conducted for a Covid-19 vaccine.
Covishield, the India-manufactured Oxford-AstraZeneca COVID-19 vaccine, was added to the UK's approved list last month.
Covaxin uses the same Vero Cell manufacturing platform as other childhood vaccines, including the inactivated polio vaccine.
Covaxin Gets WHO Nod; Union Health Minister’s Reaction
The World Health Organisation (WHO) granted Emergency Use Listing approval to India's indigenously-developed Covid vaccine, Bharat Biotech's Covaxin on Wednesday.
India's drug regulator, the Central Drugs Standards Control Organisation (CDSCO) has approved the extension of shelf life of indigenously-developed Covid-19 vaccine Covaxin from nine to 12 months.
Five more countries on Monday recognised India's vaccine certificate, after Australia recognised Bharat Biotech's Covaxin for allowing entry of travellers who had received the vaccine
This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin, and those 18 to 60 who have been vaccinated with BBIBP-CorV.
Hyderabad based Bharat Biotech is expected to submit the data by this weekend.
The Hyderabad-based Bharat Biotech had applied to the WHO on April 19 for Covaxin's Emergency Use Listing
The top court told the petitioner's counsel that it finds no error with the high court decision in the matter, and it will not entertain the petition.
Bharat Biotech recently said it has submitted all data pertaining to Covaxin to the WHO for the EUL and is awaiting feedback from the global health watchdog.
The Drugs and Comptroller General of India (DCGI) has given a go-ahead to Bharat Biotech's Covaxin for vaccination of children in the 2-18 years age group.
The Subject Expert Committee (SEC) has given the necessary approval for the administration of the anti-Covid vaccine to children.
There is no difference in antibodies produced by Covaxin and Covishield vaccines against the Covid-19 virus. This information was shared by Odisha Health Services Director Bijay Mohapatra on Monday (Sept 27).
Covaxin may soon receive Emergency Use Listing by the World Health Organisation (WHO), eventually enabling its recipients to travel abroad without mandatory quarantine, NITI Aayog's Member, Health, V.K. Paul said on Wednesday.